ArticleBMC endocrine disorders2026
Association of creatinine to body weight ratio with glycemic progression and remission in Chinese adults with prediabetes: a large-scale retrospective cohort study.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe creatinine-to-body weight ratio (Cre/BW) has been proposed as a practical surrogate marker of skeletal muscle mass. Emerging evidence highlights a notable correlation connecting Cre/BW to diabetes alongside various metabolic dysfunctions; however, its role in glycemic worsening and the restoration of normoglycemia in individuals with prediabetes has not been well defined. This study, therefore, examined the effect of Cre/BW on glycemic remission and progression among Chinese adults with prediabetes.
methodsA total of 24,506 adults with prediabetes from 11 cities in China were included in this retrospective cohort study based on health examination data. Cox proportional hazards models and subgroup analyses were used to estimate associations of Cre/BW with incident diabetes and remission to normoglycemia. Potential nonlinearity in these relationships was assessed by RCS analyses.
resultsDuring an observation period spanning 2.9 years (median), 11,170 participants (45.58%) achieved remission to normoglycemia, and 2,641 (10.78%) progressed to diabetes. In multivariable-adjusted Cox models, higher Cre/BW was linked to a greater likelihood of remission (HR = 1.41, 95% CI: 1.28-1.55, p < 0.0001) and lower hazard of progression to diabetes (HR = 0.42, 95% CI: 0.35-0.52, p < 0.0001). RCS analyses indicated a nonlinear association between Cre/BW and diabetes progression: the HR was 0.29 (95% CI: 0.20-0.40) when Cre/BW was < 1.07 μmol/L/kg and increased to 0.66 (95% CI: 0.46-0.95) when Cre/BW was ≥ 1.07 μmol/L/kg. Subgroup analyses suggested that the effect of Cre/BW on glycemic remission was more pronounced in men and in participants aged 40-50 years; a stronger effect of Cre/BW on glycemic progression was also observed among those aged < 30 years (all interaction p < 0.05).
conclusionIn adults with prediabetes, Cre/BW was linked to bidirectional changes in glycemic status: higher Cre/BW was linked to a lower hazard of progression to diabetes and a greater likelihood of remission to normoglycemia. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.